查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961146

mTOR抑制劑市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、適應症、分銷管道、地區和競爭格局分類，2021-2031年

mTOR Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Indication, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 mTOR 抑制劑市場預計將從 2025 年的 45.6 億美元成長到 2031 年的 64.6 億美元，複合年成長率為 5.98%。

這些藥物透過抑制mTOR訊號通路發揮作用，該通路調控細胞分裂，是腎細胞癌的第一線治療方法，也是預防器官移植排斥反應的重要手段。市場成長趨勢的促進因素包括全球腎臟惡性腫瘤發生率的上升以及移植手術中對有效免疫抑制的需求。美國癌症協會（ACS）的數據也支持這項需求，該協會估計，到2025年，美國將新增80,980例腎癌和腎盂癌病例。如此沉重的負擔需要持續的藥物介入。

市場概覽
預測期 2027-2031
市場規模：2025年 45.6億美元
市場規模：2031年 64.6億美元
複合年成長率：2026-2031年 5.98%
成長最快的細分市場 免疫抑制劑
最大的市場 北美洲

另一方面，長期用藥帶來的嚴重副作用是市場成長的一大障礙。這些併發症。由於這些安全隱患，醫療機構常常被迫中斷或停止用藥，導致病患依從性下降，限制了這些藥物的臨床應用。因此，儘管治療需求明確，但現有治療方法的毒性仍是充分發揮這些藥物市場潛力的主要障礙。

市場促進因素

全球腎細胞癌和乳癌發生率的上升是mTOR抑制劑市場的主要促進因素。這類藥物在阻斷促進腫瘤生長的訊號路徑方面發揮著至關重要的作用。它們被廣泛用於治療荷爾蒙受體陽性乳癌和進行性腎癌，以增強內分泌治療的效果並延緩疾病進展。這項需求直接歸因於主要醫藥市場診斷率的提高，從而需要持續推出標靶治療。根據美國癌症協會於2024年10月發布的《2024年乳癌統計》報告，預計2024年美國女性將新增約310,720例侵襲性乳癌病例，這意味著繼續依賴藥物治療來提高存活率勢在必行。

同時，器官移植手術中對免疫抑制劑的需求不斷成長，也推動了市場發展。 mTOR抑制劑藉由抑制T細胞活化，有效預防移植排斥反應。全球移植計畫的擴張，使得維持移植器官長期存活率所需的此類藥物需求持續成長。根據全球器官捐贈與移植觀察站2024年12月發布的報告顯示，2023年全球總合進行了172,397例固態器官移植手術，較上年增加9.5%。這一成長趨勢在主要區域市場也十分明顯。美國衛生資源與服務管理局（HRSA）於2025年1月宣布，2024年美國器官移植數量達到創紀錄的48,149例，凸顯了依賴長期免疫抑制治療的患者族群日益壯大。

市場挑戰

不利事件的高發生率是限制全球mTOR抑制劑市場成長的主要挑戰。在臨床應用中，從口腔炎、代謝紊亂到嚴重肺炎等毒性問題常常使治療過程複雜化，迫使醫護人員中斷治療計畫或停止治療以確保病人安全。因此，無法維持持續的治療方案會降低這些藥物的累積消耗量，對長期處方續開率產生負面影響，並抑制整體市場收入。

這個限制構成了一個重大問題，尤其是在這些治療方法的特定目標族群中，因為耐受性問題阻礙了製造商充分滿足現有患者群體的需求。根據腎癌協會統計，2024年診斷出的腎癌中約有90%為腎細胞癌。雖然這項統計數據顯示目標患者群體龐大，但由於部分患者無法耐受必要的治療療程，市場並未充分利用這項需求。耐受性問題造成的阻礙限制了有效市場佔有率，並促使人們轉向安全性更高的替代療法。

市場趨勢

隨著相關人員將關注點從疾病治療轉向延長健康壽命，老齡化和長壽療法研發投入的增加正在從根本上改變市場格局。雷帕黴素及其類似物正被深入研究，以探索其透過調節 mTOR 路徑（細胞代謝和自噬作用的核心調節因子）來延緩與老齡化相關的機能衰退的潛力。這項策略性擴張正推動大量資金流入老年學領域，以檢驗在非腫瘤領域的廣泛應用。例如，根據 Hevolution 基金會 2024 年 3 月發布的關於老年學研究機會的新聞稿，該基金會已在 2024 年撥款高達 2500 萬美元，專門用於資助加速推進健康老齡化生物學發展的計劃。

同時，為了克服第一代雷帕黴素類似物（例如mTORC1抑制不完全）的臨床局限性，新一代ATP競爭性mTOR抑制劑的研發正在推進。與傳統藥物不同，這些新型小分子化合物直接針對激酶結構域，抑制mTORC1和mTORC2複合物。這可以阻止AKT回饋激活，而AKT回饋激活通常會降低固態腫瘤的治療效果。雙重抑制劑治療難治性惡性腫瘤的臨床試驗已進入後期階段，這印證了這項技術轉變。根據2024年10月《臨床泌尿生殖系統腫瘤學雜誌》（Clinical Genitourinary Cancer）報道，一項針對新一代抑制劑sapanicertib的II期臨床試驗納入了22例轉移性尿路上皮癌患者，並評估了其安全性和克服現有療法抗藥性的潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球mTOR抑制劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（Lapamoon、 Afinitor、Tricell、Zotress、其他）
    • 適應症（腫瘤科、免疫抑制劑、器官移植等）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美mTOR抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲mTOR抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區mTOR抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲mTOR抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲mTOR抑制劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球mTOR抑制劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC.
  • AstraZeneca Plc
  • Exelixis Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Pharmaceuticals, Inc
  • Accord Healthcare Limited
  • Endo, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19165

The Global mTOR Inhibitors Market is projected to expand from a valuation of USD 4.56 Billion in 2025 to USD 6.46 Billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 5.98%. These pharmacological agents function by disrupting the mTOR signaling pathway to regulate cell division, serving as primary treatments for renal cell carcinoma and as essential prophylactic measures against organ transplant rejection. The market's upward trajectory is fundamentally underpinned by the rising global prevalence of kidney malignancies alongside the imperative need for effective immunosuppression during transplant surgeries. Data from the American Cancer Society reinforces this demand, estimating that 80,980 new cases of kidney and renal pelvis cancer will be diagnosed within the United States in 2025, a burden that necessitates sustained pharmaceutical intervention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.56 Billion
Market Size 2031USD 6.46 Billion
CAGR 2026-20315.98%
Fastest Growing SegmentImmunosuppressant
Largest MarketNorth America

Conversely, a significant obstacle to market growth is the severe profile of adverse effects linked to long-term usage, including complications such as stomatitis, metabolic disorders, and pneumonitis. These safety concerns frequently compel healthcare providers to implement dose interruptions or completely discontinue therapy, thereby undermining patient compliance and restricting the broader clinical adoption of these agents. Consequently, despite the clear therapeutic necessity, the toxicity associated with current treatment regimens remains a major impediment to maximizing the market potential of these drugs.

Market Driver

The escalating global incidence of Renal Cell Carcinoma and Breast Cancer acts as a primary catalyst for the mTOR inhibitors market, given the critical role these agents play in blocking signaling pathways that facilitate tumor proliferation. These inhibitors are extensively prescribed for hormone receptor-positive breast cancer and advanced renal malignancies to augment the efficacy of endocrine therapies and control disease progression. This demand is directly fueled by rising diagnosis rates in major pharmaceutical markets, necessitating the continued uptake of targeted interventions. According to the American Cancer Society's 'Breast Cancer Statistics, 2024' report from October 2024, approximately 310,720 new cases of invasive breast cancer are projected to be diagnosed in women in the United States during 2024, ensuring a steady reliance on pharmacological treatments to improve survival outcomes.

Simultaneously, the market is propelled by the rising demand for immunosuppressants in organ transplantation procedures, where mTOR inhibitors effectively prevent graft rejection by suppressing T-cell activation. The worldwide expansion of transplant programs has created a sustained requirement for these drugs to maintain long-term graft viability. As reported by the Global Observatory on Donation and Transplantation in December 2024, a total of 172,397 solid organ transplants were performed globally in 2023, reflecting a 9.5% increase over the previous year. This upward trend is further evidenced in key regional markets; the Health Resources and Services Administration announced in January 2025 that the United States reached a new record with 48,149 transplants performed in 2024, highlighting the expanding patient pool reliant on chronic immunosuppressive regimens.

Market Challenge

The substantial prevalence of adverse events constitutes a primary challenge that restricts the growth of the global mTOR inhibitors market. Clinical administration is frequently complicated by toxicity issues, ranging from stomatitis and metabolic disorders to severe pneumonitis, which often force healthcare professionals to interrupt dosage schedules or discontinue therapy entirely to ensure patient safety. Consequently, the inability to maintain consistent treatment regimens reduces the cumulative consumption of these drugs and negatively affects long-term prescription renewal rates, thereby dampening overall market revenue.

This limitation is particularly critical regarding the specific target demographic for these therapies, as intolerance prevents manufacturers from fully servicing the available patient pool. According to the Kidney Cancer Association, renal cell carcinoma accounted for approximately 90 percent of all kidney cancer diagnoses in 2024. While this statistic indicates a substantial target population, the market fails to fully capitalize on this demand because a segment of these patients cannot tolerate the necessary therapeutic duration. The friction caused by intolerance limits the realizable market share and discourages broader adoption in favor of alternative treatments with more favorable safety profiles.

Market Trends

The rising R&D investment in anti-aging and longevity therapeutics is fundamentally reshaping the market landscape as stakeholders pivot from solely treating pathology to extending healthspan. Rapamycin and its analogs are being rigorously investigated for their potential to delay age-related decline by modulating the mTOR pathway, which serves as a central regulator of cellular metabolism and autophagy. This strategic expansion is catalyzing substantial capital flows into geroscience to validate these agents for broader non-oncological applications. For instance, according to the Hevolution Foundation's March 2024 press release regarding geroscience research opportunities, the organization allocated up to $25 million in 2024 specifically to fund projects accelerating progress in healthy aging biology.

Simultaneously, the advancement of next-generation ATP-competitive mTOR inhibitors is gaining traction to overcome the clinical limitations of first-generation rapalogs, such as incomplete mTORC1 inhibition. Unlike traditional agents, these novel small molecules directly target the kinase domain to block both mTORC1 and mTORC2 complexes, thereby preventing the feedback activation of AKT that often compromises therapeutic efficacy in solid tumors. This technological shift is evidenced by the progression of dual inhibitors into advanced clinical evaluations for refractory malignancies. According to an October 2024 article in Clinical Genitourinary Cancer, a Phase II study assessing the next-generation inhibitor sapanisertib enrolled 22 patients with metastatic urothelial carcinoma to evaluate its safety and potential to overcome resistance to prior therapies.

Key Market Players

  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC.
  • AstraZeneca Plc
  • Exelixis Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Zydus Pharmaceuticals, Inc
  • Accord Healthcare Limited
  • Endo, Inc.

Report Scope

In this report, the Global mTOR Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mTOR Inhibitors Market, By Product Type

  • Rapamune
  • Afinitor
  • Torisel
  • Zortress
  • Other

mTOR Inhibitors Market, By Indication

  • Oncology
  • Immunosuppressant
  • Organ Transplantation
  • Other

mTOR Inhibitors Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

mTOR Inhibitors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mTOR Inhibitors Market.

Available Customizations:

Global mTOR Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mTOR Inhibitors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Rapamune, Afinitor, Torisel, Zortress, Other)
    • 5.2.2. By Indication (Oncology, Immunosuppressant, Organ Transplantation, Other)
    • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America mTOR Inhibitors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States mTOR Inhibitors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada mTOR Inhibitors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico mTOR Inhibitors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Distribution Channel

7. Europe mTOR Inhibitors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany mTOR Inhibitors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. France mTOR Inhibitors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom mTOR Inhibitors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy mTOR Inhibitors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain mTOR Inhibitors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific mTOR Inhibitors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China mTOR Inhibitors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India mTOR Inhibitors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan mTOR Inhibitors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea mTOR Inhibitors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia mTOR Inhibitors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa mTOR Inhibitors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia mTOR Inhibitors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. UAE mTOR Inhibitors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. South Africa mTOR Inhibitors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Distribution Channel

10. South America mTOR Inhibitors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil mTOR Inhibitors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Colombia mTOR Inhibitors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Argentina mTOR Inhibitors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global mTOR Inhibitors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Teva Pharmaceutical Industries Ltd.
  • 15.4. Hikma Pharmaceuticals PLC.
  • 15.5. AstraZeneca Plc
  • 15.6. Exelixis Inc.
  • 15.7. Dr. Reddy's Laboratories Ltd.
  • 15.8. Zydus Pharmaceuticals, Inc
  • 15.9. Accord Healthcare Limited
  • 15.10. Endo, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer